NovaBay Pharmaceuticals
About: NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
Employees: 26
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
3.89% less ownership
Funds ownership: 4.75% [Q1] → 0.85% (-3.89%) [Q2]
40% less funds holding
Funds holding: 15 [Q1] → 9 (-6) [Q2]
44% less capital invested
Capital invested by funds: $45.6K [Q1] → $25.4K (-$20.1K) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 8
Research analyst outlook
We haven’t received any recent analyst ratings for NBY.
Financial journalist opinion
Based on 3 articles about NBY published over the past 30 days